Figure 2.

Kaplan-Meier curves of PFS in patients with WM with MYD88^MUT in relation to CXCR4, TP53, and TERT mutational status. Pooled analysis of patients with MYD88^MUT, including 98 treated with zanubrutinib and 92 treated with ibrutinib. Kaplan-Meier curves of PFS were presented according to the mutational status of (A) CXCR4, (B) TP53, and (C) TERT. PFS in patients with CXCR4^MUT, TP53^MUT, and TERT^MUT trended toward less favorable outcomes than in patients with the respective WT alleles. HR and P values were estimated using a Cox regression model with CXCR4 (WT and MUT), TP53 (WT and MUT), TERT (WT and MUT) mutational status and treatment arms as covariates. WT is the reference group.